Developer docs
API playgroundTry for free, no card

Search company profiles

NEXT Oncology

Full company profile

uuid0009ray

Namestring
NEXT Oncology
Legal namestring
NEXT Oncology
Company typeenum
Private
Founded yearint
2018
Descriptiontext

NEXT Oncology is a Phase I oncology clinical trial site network founded in 2018 by Dr. Anthony Tolcher and headquartered in San Antonio, Texas. The network operates nine clinical trial sites across the United States, Spain, Japan, and Brazil, and has enrolled more than 3,200 patients since inception, with over 1,000 patients treated annually. In 2025, NEXT Oncology aligned with the Avacare Clinical Research Network within IQVIA (NYSE: IQV), embedding the network into a global CRO/site infrastructure. The organization conducts first-in-human and early-stage oncology trials for pharmaceutical and biotech sponsors, with a portfolio that spans cytotoxic agents, immunotherapies, and antibody-drug conjugates (ADCs). It has produced 25 abstracts and presentations at ASCO and holds the "Preferred Oncology Phase 1 Site" designation since 2025. Awards include the 2024 and 2025 Health Care Hero recognition from the San Antonio Business Journal.

The company's core offering is contracted Phase I clinical trial execution, supported by a proprietary real-time collaboration platform that links sites, CROs, and sponsors. Strategic partnerships extend its referral and operational reach: Texas Oncology provides access to 400+ referring oncologists; Virginia Cancer Specialists, Quirónsalud Group (Spain), Kansai Medical University (Japan, joint venture), Oncologia D'Or and IDOR (Brazil) extend clinical capacity internationally. CRO partnerships with Crown Bioscience and Worldwide Clinical Trials, plus a licensing agreement with MatTek Life Sciences, broaden the sponsor pipeline. The MediLink Therapeutics partnership (October 2023) added ADC trial capability.

NEXT Oncology operates a B2B revenue model: pharmaceutical and biotech sponsors fund trial contracts, while patients receive access at no cost. Pricing is negotiated through multi-year contracts. The 2025 IQVIA/Avacare integration provides shared infrastructure, data systems, and global sponsor relationships, reducing standalone go-to-market burden while expanding commercial reach across the sponsor ecosystem.

Short descriptiontext

NEXT Oncology is a Phase I oncology clinical trial site network operating nine global locations, founded in 2018 by Dr. Anthony Tolcher, that conducts early-stage cancer drug trials for pharmaceutical and biotech sponsors serving advanced cancer patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Antonio, United States
HQ citystring
San Antonio
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Phase I clinical trials, oncology research services, early phase oncology, cancer clinical research, anticancer drug development
Industry1 code
PRIMARYHLAKAFAB
Medical Oncology
NAICS code2 codes
  • Offices of Physicians62111
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Clinical Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Services for Pharma/Biotech Sponsors
TypeProfessional Services
Description

NEXT Oncology conducts Phase I clinical trials on behalf of pharmaceutical and biotechnology companies, earning fees for site services, patient enrollment, and trial execution. As part of the IQVIA/Avacare network, the company serves as a specialized clinical research site generating revenue through contracted research services.

nextoncology.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Clinical trial research services for pharmaceutical/biotech sponsors
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is B2B, negotiated between NEXT Oncology and drug sponsors for conducting Phase I trials. Patients participate at no cost.

nextoncology.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NEXT Oncology operates a global network of Phase I clinical trial centers that conduct early-phase oncology clinical pharmacology trials on behalf of pharmaceutical and biotechnology sponsors. The company provides advanced cancer patients access to the newest investigational anticancer agents, including first-in-human studies, antibody-drug conjugates, and KRAS-targeted therapies. Services include rapid study site activation, patient enrollment, and real-time sponsor collaboration through a proprietary data exchange platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 3,200+ patients treated since 2018 founding across 9 global locations
+2 more records
Product overview1 text field

NEXT Oncology is a Phase 1 clinical trial center network dedicated to providing advanced cancer patients access to the newest anticancer treatments through Phase I clinical pharmacology trials. The company operates a multi-site network model with locations across North America (San Antonio, Austin, Dallas, Houston, Virginia), Europe (Barcelona, Madrid), and Asia-Pacific (Japan), as well as Brazil. As part of the Avacare Clinical Research Network within IQVIA, NEXT Oncology connects biotechnology and pharmaceutical sponsors with patients to accelerate clinical development of novel oncology therapies. The core offering is Phase I clinical trial conduct, supplemented by a patient portal for trial management.

Product and service4 records
1Phase I Clinical Trials
CategoryClinical Research Services
2Clinical Trial Patient Access Program
CategoryClinical Research Services
3San Antonio Phase I Clinical Trial Center
CategoryClinical Research Services - Site Network
4Austin Phase I Clinical Trial Center
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Kansai Medical University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Joint venture partnership establishing NEXT Oncology Japan at Kansai Medical University Hospital in Osaka, Japan. Dr. Toshio Shimizu serves as Director of NEXT Oncology Japan. The site is designated as 'Preferred Oncology Phase 1 Site' by global pharmaceutical sponsors since 2025. Prof. Shimizu previously completed clinical fellowship in San Antonio under Dr. Tolcher's mentorship.

nextoncology.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-07-29
Description

Strategic partnership for expansion into Brazil, making NEXT Oncology one of the world's largest Phase I Cancer Trial organizations with global presence across North America, Europe, Latin America, and Asia-Pacific.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-05-01
Description

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, extended its partnership with NEXT Oncology. Crown Bioscience is one of the world's largest Phase I Oncology Clinical Trial networks.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-10-09
Description

Collaboration on Phase 1 First in Human Clinical trial for an antibody drug conjugate (ADC) using MediLink's YL201 ADC platform. Features real-time exchange of patient progress and outcomes, with 'bench to bedside and back' approach using proprietary technology enabling shortened drug development timelines.

Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-05-18
Description

Worldwide Clinical Trials, a leading global full-service CRO, expanded its Site Alliance Collaboration to include NEXT Oncology in Spain as part of new partnerships across the United States and Europe.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

In 2025, NEXT Oncology joined the IQVIA family as part of the Avacare Clinical Research Network, IQVIA's network of specialized clinical research sites. This strategic move unlocks accelerated growth opportunities through enhanced collaboration, expanded capabilities and deeper alignment with IQVIA's patient- and site-centric approach.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture forming NEXT Virginia with Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia. Both practices are part of The US Oncology Network. VCS Research Institute has the largest clinical trial program in the MidAtlantic area.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Agreement between NEXT Oncology and Quirónsalud Group established research program providing highest possible number of early phase clinical trials in Spain, with locations in Barcelona and Madrid. Offers quality, safety, and specialized care to patients while ensuring scientific rigor.

10The US Oncology Network
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Virginia Cancer Specialists and Texas Oncology, NEXT's US partners, are both practices within The US Oncology Network, the largest network of its kind in the United States providing NEXT Oncology unprecedented opportunities to transform clinical trials.

nextoncology.com
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Sarah Cannon Research Institute
TypeDirect peer
Description

The premier US Phase I oncology clinical trial site network, operating across multiple US cities. Highly comparable to NEXT Oncology in core offering (early-phase oncology trials for pharma sponsors), patient referral model, and sponsor relationships.

TypeDirect peer
Description

One of the largest global Phase I oncology clinical trial networks, headquartered in San Antonio — the same metro as NEXT Oncology. Directly comparable mission, scale, and sponsor-driven B2B revenue model focused on first-in-human oncology studies.

3The US Oncology Network
TypeBroad incumbent
Description

The largest network of community-based oncology practices in the US; NEXT's Texas Oncology and Virginia Cancer Specialists partners are both US Oncology practices. Comparable in oncology patient reach and clinical research infrastructure, though US Oncology is broader across trial phases.

TypeBroad incumbent
Description

NEXT's parent-affiliate (via the Avacare Clinical Research Network) and the world's largest CRO. Comparable as an oncology clinical research services provider with global reach, though IQVIA operates across many therapeutic areas and trial phases.

TypeBroad incumbent
Description

Premier US academic comprehensive cancer center running a large Phase I oncology program with strong sponsor relationships and scientific output. Overlaps with NEXT in early-phase oncology trials and patient referrals, but operates a much broader clinical and research mandate.

TypeDirect peer
Description

Large US community oncology practice with a significant Phase I clinical trials program for pharma sponsors. Comparable in community-based oncology patient access and early-phase trial conduct, though smaller in global footprint than NEXT.

TypeBroad incumbent
Description

Global full-service CRO that has a Site Alliance Collaboration partnership with NEXT Oncology in Spain. Comparable as a clinical research services provider serving pharma sponsors, though it operates across all trial phases and multiple therapeutic areas.

TypeBroad incumbent
Description

World-leading academic cancer center with a sizable early-phase clinical trials program and deep sponsor relationships. Comparable in Phase I oncology trial execution and scientific credibility, though much broader in scope and academic-versus-community positioning.

TypeBroad incumbent
Description

Major global CRO with significant oncology clinical research services. Comparable as a sponsor-facing clinical research services provider, though it is much larger and diversified across therapeutic areas and trial phases.

TypeEmerging player
Description

Global preclinical and translational CRO with an extended partnership with NEXT Oncology; operates one of the world's largest Phase I oncology clinical trial networks. Comparable in early-phase oncology focus and sponsor services, though more weighted toward preclinical/ translational work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NEXT Oncology

Oncology Clinical Research Servicesnextoncology.com

NEXT Oncology is a Phase I oncology clinical trial site network operating nine global locations, founded in 2018 by Dr. Anthony Tolcher, that conducts early-stage cancer drug trials for pharmaceutical and biotech sponsors serving advanced cancer patients.

What NEXT Oncology does

NEXT Oncology is a Phase I oncology clinical trial site network founded in 2018 by Dr. Anthony Tolcher and headquartered in San Antonio, Texas. The network operates nine clinical trial sites across the United States, Spain, Japan, and Brazil, and has enrolled more than 3,200 patients since inception, with over 1,000 patients treated annually. In 2025, NEXT Oncology aligned with the Avacare Clinical Research Network within IQVIA (NYSE: IQV), embedding the network into a global CRO/site infrastructure. The organization conducts first-in-human and early-stage oncology trials for pharmaceutical and biotech sponsors, with a portfolio that spans cytotoxic agents, immunotherapies, and antibody-drug conjugates (ADCs). It has produced 25 abstracts and presentations at ASCO and holds the "Preferred Oncology Phase 1 Site" designation since 2025. Awards include the 2024 and 2025 Health Care Hero recognition from the San Antonio Business Journal.

The company's core offering is contracted Phase I clinical trial execution, supported by a proprietary real-time collaboration platform that links sites, CROs, and sponsors. Strategic partnerships extend its referral and operational reach: Texas Oncology provides access to 400+ referring oncologists; Virginia Cancer Specialists, Quirónsalud Group (Spain), Kansai Medical University (Japan, joint venture), Oncologia D'Or and IDOR (Brazil) extend clinical capacity internationally. CRO partnerships with Crown Bioscience and Worldwide Clinical Trials, plus a licensing agreement with MatTek Life Sciences, broaden the sponsor pipeline. The MediLink Therapeutics partnership (October 2023) added ADC trial capability.

NEXT Oncology operates a B2B revenue model: pharmaceutical and biotech sponsors fund trial contracts, while patients receive access at no cost. Pricing is negotiated through multi-year contracts. The 2025 IQVIA/Avacare integration provides shared infrastructure, data systems, and global sponsor relationships, reducing standalone go-to-market burden while expanding commercial reach across the sponsor ecosystem.

NEXT Oncology firmographics

Firmographics
Name
NEXT Oncology
Legal name
NEXT Oncology
Website
https://nextoncology.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
NEXT Oncology is a Phase I oncology clinical trial site network operating nine global locations, founded in 2018 by Dr. Anthony Tolcher, that conducts early-stage cancer drug trials for pharmaceutical and biotech sponsors serving advanced cancer patients.
Ownership category
akta.pro rank

NEXT Oncology industry classification

Industry
Product category
Oncology Clinical Research Services
NAICS
Offices of Physicians (62111), Scientific Research and Development Services (5417)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAKAFAB
Medical Oncology

Keywords

  • Phase I clinical trials
  • Oncology research services
  • Early phase oncology
  • Cancer clinical research
  • Anticancer drug development

Where NEXT Oncology is headquartered

Location

Headquarters

HQ city
San Antonio
HQ country
United States
HQ region
North America

Offices9 records

Markets served

NEXT Oncology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Trial Services for Pharma/Biotech Sponsors: NEXT Oncology conducts Phase I clinical trials on behalf of pharmaceutical and biotechnology companies, earning fees for site services, patient enrollment, and trial execution. As part of the IQVIA/Avacare network, the company serves as a specialized clinical research site generating revenue through contracted research services.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractClinical trial research services for pharmaceutical/biotech sponsors

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

NEXT Oncology product offering

Product offering

Core offering

NEXT Oncology operates a global network of Phase I clinical trial centers that conduct early-phase oncology clinical pharmacology trials on behalf of pharmaceutical and biotechnology sponsors. The company provides advanced cancer patients access to the newest investigational anticancer agents, including first-in-human studies, antibody-drug conjugates, and KRAS-targeted therapies. Services include rapid study site activation, patient enrollment, and real-time sponsor collaboration through a proprietary data exchange platform.

Product overview

NEXT Oncology is a Phase 1 clinical trial center network dedicated to providing advanced cancer patients access to the newest anticancer treatments through Phase I clinical pharmacology trials. The company operates a multi-site network model with locations across North America (San Antonio, Austin, Dallas, Houston, Virginia), Europe (Barcelona, Madrid), and Asia-Pacific (Japan), as well as Brazil. As part of the Avacare Clinical Research Network within IQVIA, NEXT Oncology connects biotechnology and pharmaceutical sponsors with patients to accelerate clinical development of novel oncology therapies. The core offering is Phase I clinical trial conduct, supplemented by a patient portal for trial management.

Differentiator

Problem solved

Functional benefit

Products and services

  • Phase I Clinical Trials
  • Clinical Trial Patient Access Program
  • San Antonio Phase I Clinical Trial Center
  • Austin Phase I Clinical Trial Center

Quantifiable outcome

  • 3,200+ patients treated since 2018 founding across 9 global locations
  • +2 more outcomes

Companies that use NEXT Oncology

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

NEXT Oncology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

NEXT Oncology partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and strategic.

  • Kansai Medical UniversitycoreStrategic or Co-development Partner · 5 November 2025Joint venture partnership establishing NEXT Oncology Japan at Kansai Medical University Hospital in Osaka, Japan. Dr. Toshio Shimizu serves as Director of NEXT Oncology Japan. The site is designated as 'Preferred Oncology Phase 1 Site' by global pharmaceutical sponsors since 2025. Prof. Shimizu previously completed clinical fellowship in San Antonio under Dr. Tolcher's mentorship.
  • Oncologia D'Or and IDORmajorStrategic or Co-development Partner · 29 July 2025Strategic partnership for expansion into Brazil, making NEXT Oncology one of the world's largest Phase I Cancer Trial organizations with global presence across North America, Europe, Latin America, and Asia-Pacific.
  • Crown BiosciencestrategicTechnology or Integration · 1 May 2025Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, extended its partnership with NEXT Oncology. Crown Bioscience is one of the world's largest Phase I Oncology Clinical Trial networks.
  • MediLink TherapeuticsstrategicStrategic or Co-development Partner · 9 October 2023Collaboration on Phase 1 First in Human Clinical trial for an antibody drug conjugate (ADC) using MediLink's YL201 ADC platform. Features real-time exchange of patient progress and outcomes, with 'bench to bedside and back' approach using proprietary technology enabling shortened drug development timelines.
  • Worldwide Clinical TrialsstrategicChannel Partner/ Reseller/ Distributor · 18 May 2023Worldwide Clinical Trials, a leading global full-service CRO, expanded its Site Alliance Collaboration to include NEXT Oncology in Spain as part of new partnerships across the United States and Europe.
  • IQVIA / Avacare Clinical Research NetworkcoreStrategic or Co-development PartnerIn 2025, NEXT Oncology joined the IQVIA family as part of the Avacare Clinical Research Network, IQVIA's network of specialized clinical research sites. This strategic move unlocks accelerated growth opportunities through enhanced collaboration, expanded capabilities and deeper alignment with IQVIA's patient- and site-centric approach.
  • Texas OncologycoreStrategic or Co-development PartnerPartnership with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network.
  • Virginia Cancer SpecialistscoreStrategic or Co-development PartnerJoint venture forming NEXT Virginia with Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia. Both practices are part of The US Oncology Network. VCS Research Institute has the largest clinical trial program in the MidAtlantic area.
  • Quirónsalud GroupcoreStrategic or Co-development PartnerAgreement between NEXT Oncology and Quirónsalud Group established research program providing highest possible number of early phase clinical trials in Spain, with locations in Barcelona and Madrid. Offers quality, safety, and specialized care to patients while ensuring scientific rigor.
  • The US Oncology NetworkstrategicStrategic or Co-development PartnerVirginia Cancer Specialists and Texas Oncology, NEXT's US partners, are both practices within The US Oncology Network, the largest network of its kind in the United States providing NEXT Oncology unprecedented opportunities to transform clinical trials.

Scale indicators4 records

Recent moves12 records

Expansion highlights6 records

NEXT Oncology competitors and assessment

Company assessment

Direct peers

  • Sarah Cannon Research Institute: The premier US Phase I oncology clinical trial site network, operating across multiple US cities. Highly comparable to NEXT Oncology in core offering (early-phase oncology trials for pharma sponsors), patient referral model, and sponsor relationships.
  • START (South Texas Accelerated Research Therapeutics): One of the largest global Phase I oncology clinical trial networks, headquartered in San Antonio — the same metro as NEXT Oncology. Directly comparable mission, scale, and sponsor-driven B2B revenue model focused on first-in-human oncology studies.
  • Florida Cancer Specialists & Research Institute: Large US community oncology practice with a significant Phase I clinical trials program for pharma sponsors. Comparable in community-based oncology patient access and early-phase trial conduct, though smaller in global footprint than NEXT.

Broad incumbents

  • The US Oncology Network: The largest network of community-based oncology practices in the US; NEXT's Texas Oncology and Virginia Cancer Specialists partners are both US Oncology practices. Comparable in oncology patient reach and clinical research infrastructure, though US Oncology is broader across trial phases.
  • IQVIA: NEXT's parent-affiliate (via the Avacare Clinical Research Network) and the world's largest CRO. Comparable as an oncology clinical research services provider with global reach, though IQVIA operates across many therapeutic areas and trial phases.
  • MD Anderson Cancer Center: Premier US academic comprehensive cancer center running a large Phase I oncology program with strong sponsor relationships and scientific output. Overlaps with NEXT in early-phase oncology trials and patient referrals, but operates a much broader clinical and research mandate.
  • Worldwide Clinical Trials: Global full-service CRO that has a Site Alliance Collaboration partnership with NEXT Oncology in Spain. Comparable as a clinical research services provider serving pharma sponsors, though it operates across all trial phases and multiple therapeutic areas.
  • Memorial Sloan Kettering Cancer Center: World-leading academic cancer center with a sizable early-phase clinical trials program and deep sponsor relationships. Comparable in Phase I oncology trial execution and scientific credibility, though much broader in scope and academic-versus-community positioning.
  • ICON plc: Major global CRO with significant oncology clinical research services. Comparable as a sponsor-facing clinical research services provider, though it is much larger and diversified across therapeutic areas and trial phases.

Emerging players

  • Crown Bioscience: Global preclinical and translational CRO with an extended partnership with NEXT Oncology; operates one of the world's largest Phase I oncology clinical trial networks. Comparable in early-phase oncology focus and sponsor services, though more weighted toward preclinical/ translational work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

NEXT Oncology social profiles

Digital presence

NEXT Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NEXT Oncology leadership team

Management profile

Number of profiles

Profiles8 records

NEXT Oncology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NEXT Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NEXT Oncology

What does NEXT Oncology do?

NEXT Oncology operates a global network of Phase I clinical trial centers that conduct early-phase oncology clinical pharmacology trials on behalf of pharmaceutical and biotechnology sponsors. The company provides advanced cancer patients access to the newest investigational anticancer agents, including first-in-human studies, antibody-drug conjugates, and KRAS-targeted therapies. Services include rapid study site activation, patient enrollment, and real-time sponsor collaboration through a proprietary data exchange platform.

Is NEXT Oncology a public or private company?

NEXT Oncology is a private company. It is classified as corporate owned and is currently operating.

When was NEXT Oncology founded?

NEXT Oncology was founded in 2018. It employs 101 to 250 people.

Where is NEXT Oncology based?

NEXT Oncology is headquartered in San Antonio, United States, in the North America region.

How does NEXT Oncology make money?

One revenue line is on record: clinical Trial Services for Pharma/Biotech Sponsors.

Who are NEXT Oncology's main competitors?

Direct peers on record are Sarah Cannon Research Institute, START (South Texas Accelerated Research Therapeutics) and Florida Cancer Specialists & Research Institute. Broad incumbents are The US Oncology Network, IQVIA, MD Anderson Cancer Center, Worldwide Clinical Trials, Memorial Sloan Kettering Cancer Center and ICON plc. Crown Bioscience is listed as an emerging player.

Does NEXT Oncology have an API?

No public API is recorded for NEXT Oncology.

What industry is NEXT Oncology in?

NEXT Oncology's product category is Oncology Clinical Research Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology. Its NAICS code is 62111 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CuretodayWhat Is the Difference Between a Clinical Trial and a Real-World Study?Dr. Alexander Spira, chief scientific officer for NEXT Oncology, discussed the distinction between clinical trials and real-world studies regarding the effectiveness of Lumakras (sotorasib) at the IASLC 2025 World Conference on Lung Cancer in Barcelona. The interview highlighted that real-world studies utilize commercially available databases to assess patient tolerance and quality of life outside strict clinical enrollment criteria.AJMCSarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCOAlexander Spira, chief scientific officer of NEXT Oncology, highlights that the extreme rarity and molecular diversity of sarcoma complicate clinical trial design and limit biomarker-driven treatment options. He recommends universal next-generation sequencing for patients to identify rare targetable mutations or clinical trial eligibility, despite the current lack of approved therapies specifically for soft tissue sarcoma.PR NewswireBreakthrough Targeted Therapy Shows Promise for KRAS‑Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key RoleVirginia Cancer Specialists announced its participation as a leading clinical trial site in a landmark study evaluating daraxonrasib, a first-in-class targeted oral therapy for advanced KRAS-mutated pancreatic cancer, with results published in The New England Journal of Medicine showing nearly 90% disease control. Positive Phase 3 results reported in April 2026 further confirmed the therapy's clinical benefit and signal a potential new standard of care for a cancer historically resistant to targeted treatment. Virginia Cancer Specialists and NEXT Oncology conducted the research through their joint venture partnership, making innovative therapies accessible to patients in community settings.AxiosScoop: Iqvia to acquire Next OncologyClinical research giant Iqvia has agreed to acquire Next Oncology, a San Antonio-based network of cancer clinical trial centers. The acquisition signals continued consolidation in the clinical trials sector as companies seek to strengthen their oncology capabilities. The deal comes as oncology trial data becomes an increasingly valuable asset amid competition, particularly noting that China's patient recruitment and site expansion is outpacing the United States.American City Business JournalsNext Oncology expanding to Dallas amid growth pushNext Oncology, a San Antonio-based cancer research company, is entering the Dallas market. CEO Dr. Anthony Tolcher said the organization is on an expedited course for expansion in the U.S. and Europe.PR NewswireBJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid TumorsBJ Bioscience Inc. announced on December 9, 2019 that the first patient was successfully dosed on December 4, 2019 in the first-in-human trial of its BJ-001 program for locally advanced/metastatic solid tumors at Next Oncology in San Antonio, Texas. The Phase 1a trial employs an accelerated dose escalation design followed by a traditional 3+3 algorithm to assess safety, tolerability, and identify the maximum tolerated dose and/or recommended Phase 2 dose, both as a single agent and in combination with an anti-PD-1 antibody. As of December 8, 2019, the patient had completed C1D5 with no cytokine release syndrome or other adverse events observed.GlobeNewswireCrownBio and NEXT Oncology Announce Strategic PDX Model PartnershipCrown Bioscience and NEXT Oncology announced a strategic partnership to provide clinically-relevant PDX models for preclinical drug development. The agreement makes CrownBio the exclusive global commercialization partner for NEXT Oncology's primary tumor PDX models for five years, adding 350 models with characterization data and patient history. Initial models are expected ready for client studies by mid-2020.